News Image

NASDAQ:HALO, an undervalued stock with good fundamentals.

By Mill Chart

Last update: Feb 9, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a hidden gem identified by our stock screening tool, featuring undervaluation and robust fundamentals. NASDAQ:HALO showcases decent financial health and profitability, coupled with an attractive price. Let's dig deeper into the analysis.

Deciphering NASDAQ:HALO's Valuation Rating

ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:HALO was assigned a score of 9 for valuation:

  • 97.80% of the companies in the same industry are more expensive than HALO, based on the Price/Earnings ratio.
  • HALO's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.01.
  • A Price/Forward Earnings ratio of 9.84 indicates a reasonable valuation of HALO.
  • 98.81% of the companies in the same industry are more expensive than HALO, based on the Price/Forward Earnings ratio.
  • HALO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.53.
  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 95.59% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 97.80% of the companies are valued more expensively.
  • HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HALO has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as HALO's earnings are expected to grow with 25.83% in the coming years.

Profitability Assessment of NASDAQ:HALO

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:HALO has achieved a 8:

  • HALO has a better Return On Assets (13.41%) than 98.64% of its industry peers.
  • Looking at the Return On Equity, with a value of 101.89%, HALO belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • HALO's Return On Invested Capital of 14.39% is amongst the best of the industry. HALO outperforms 97.63% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for HALO is significantly above the industry average of 13.61%.
  • The last Return On Invested Capital (14.39%) for HALO is well below the 3 year average (36.78%), which needs to be investigated, but indicates that HALO had better years and this may not be a problem.
  • With an excellent Profit Margin value of 32.53%, HALO belongs to the best of the industry, outperforming 98.47% of the companies in the same industry.
  • In the last couple of years the Profit Margin of HALO has grown nicely.
  • HALO has a Operating Margin of 40.35%. This is amongst the best in the industry. HALO outperforms 98.98% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • HALO has a Gross Margin of 76.68%. This is amongst the best in the industry. HALO outperforms 85.59% of its industry peers.

Health Analysis for NASDAQ:HALO

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:HALO has achieved a 7 out of 10:

  • HALO has an Altman-Z score of 3.31. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • HALO has a better Altman-Z score (3.31) than 72.54% of its industry peers.
  • The Debt to FCF ratio of HALO (4.24) is better than 94.92% of its industry peers.
  • A Current Ratio of 7.63 indicates that HALO has no problem at all paying its short term obligations.
  • HALO has a Current ratio of 7.63. This is in the better half of the industry: HALO outperforms 67.80% of its industry peers.
  • HALO has a Quick Ratio of 6.51. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • HALO's Quick ratio of 6.51 is fine compared to the rest of the industry. HALO outperforms 62.03% of its industry peers.

Assessing Growth for NASDAQ:HALO

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:HALO has received a 8 out of 10:

  • The Earnings Per Share has grown by an nice 12.96% over the past year.
  • HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 42.34% yearly.
  • Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 34.42%.
  • HALO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.83% yearly.
  • Based on estimates for the next years, HALO will show a very strong growth in Earnings Per Share. The EPS will grow by 25.42% on average per year.
  • Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 18.74% on average per year.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of HALO

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/30/2024, 8:40:54 AM)

43.03

+0.27 (+0.63%)

HALO News

News Imagea day ago - ChartmillNASDAQ:HALO is probably undervalued for the fundamentals it is displaying.

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

News Image9 days ago - Halozyme Therapeutics, Inc.Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee...

News Image13 days ago - Market News VideoHALO July 19th Options Begin Trading
News Image14 days ago - Investor's Business DailyHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

News Image16 days ago - Investor's Business DailyCatalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

News Image16 days ago - ChartmillWhile growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...

News Image21 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image22 days ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...

News Image23 days ago - InvestorPlaceHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image23 days ago - BusinessInsiderHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...

HALO Links
Follow us for more